Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-28T05:33:51.491Z Has data issue: false hasContentIssue false

OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM

Published online by Cambridge University Press:  18 December 2023

Guy Boudreau
Affiliation:
Centre Hospitalier Universitaire de Montréal (CHUM), Montréal, Quebec, Canada
Ian Finkelstein
Affiliation:
Toronto Headache & Pain Clinic, Toronto, Ontario, Canada
Corrie Graboski
Affiliation:
Island Health, Brentwood Bay, British Columbia, Canada
May Ong
Affiliation:
St Paul Hospital, Vancouver, British Columbia, Canada
Suzanne Christie
Affiliation:
University of Ottawa (Neurology), Ottawa, Ontario, Canada
Katherine Sommer
Affiliation:
AbbVie Inc., Marlow, Buckinghamshire, UK
Meetu Bhogal
Affiliation:
AbbVie Inc., Markham, Ontario, Canada
Goran Davidovic
Affiliation:
AbbVie Inc., Markham, Ontario, Canada
Werner J. Becker
Affiliation:
Department of Clinical Sciences, University of Calgary, Calgary, Alberta, Canada
Rights & Permissions [Opens in a new window]

Abstract

Type
Corrigendum
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

In the original publication of the above article,1 the following errors were identified:

  • On page 4, in the 2nd paragraph of the Baseline Demographics, CM History, and Medication Use History section, the denominator for the total population (n=184) is presented when it should be the number of yes responses (n=145). The correct values for antidepressants and anticonvulsants should be 90/145 (62.1%) and 81/145 (55.9%), respectively.

  • On page 5 in Table 1 the Acute Medication Use row, the extraneous n (%) should be deleted.

  • On page 6, in Table 2A Tx 3 to Tx 4 for 12 weeks 20 (20.0) should be replaced with 30 (20.0).

  • On page 6, in Table 2B the mean (SD) total dose for Tx3 of 172 (18) should be replaced with 172 (19).

  • On page 6, on the 2nd paragraph of column 1, “Tx7/Final Visit”, Final Visit should be deleted.

  • On page 6, on the 1st paragraph of column 2 the SD for mean change in moderate/severe headache days should be changed from 5.6 (7.0) to 5.6 (7.1).

  • On page 6, on the 1st paragraph of column 2, “Tx7/Final Visit”, Final Visit should be deleted.

  • On page 7, Figure 2 footnote A to be revised to read: For mean MSQ scores, n (missing) data for role restrictive, role preventive, and emotional function at baseline and Tx4 were 184 (0) and 150 (0), respectively. The n (missing) for the final visit were 143 (41) for role restrictive and role preventive and 142 (42) for emotional function.

  • On page 7, Figure 2 footnote B to be revised to read: For mean change from baseline MSQ scores, n (missing) data for role restrictive, role preventive, and emotional function at baseline and Tx4 were 184 (0) and 150 (0), respectively. The n (missing) for the final visit were 143 (41) for role restrictive and role preventive and 142 (42) for emotional function; within group minimal important differences for MSQ v. 2.1 are displayed for reference37. Error bars represent standard deviations. Statistical significance is shown as *p < 0.0001. n, number of participants; Tx, treatment.

  • On page 7, column 1, paragraph 1, line 4, “Tx7/” should be deleted.

  • On page 7, column 2, line 1, “Tx7/” should be deleted.

  • On page 8, Figure 3 footnote, 3rd line from end “Missing data include…final visit” should be revised to read “The n (missing) data for baseline, Tx1, Tx2, Tx3, Tx4, Tx7, and final visit were 162 (22), 150 (34), 142 (32), 134 (29), 121 (29), 104 (24), and 126 (58).”

  • On page 8, the last sentence of the footnote for Figure 3 should be updated from “Participants with <5 d of diary data…” to “Participants with <15 d of diary data…”

  • On page 8, in 2nd paragraph of the 1st column the control of headache severity results should be updated from “103/123 83.7% [Tx7]” to “100/120 83.3% [final visit].”

  • On page 9, Figure 4 A-C, Change Final Visit to Last Visit.

  • On page 9, Figure 4 footnote penultimate sentence “Missing data include…panels (A) (C), should be revised to read “The n (missing) data for Tx2, Tx3, Tx4, Tx7, and last visit were 174 (0), 161 (2), 150 (0), 127 (1), and 141 (43), respectively.”

  • On page 10, in Table 3, insert row “Influenza 6 (3.3) 6 events” above Bronchitis and move Brow ptosis to above Pneumonia.

  • On page 10, in Table 3 update Bronchitis to 5 (2.7%) 5 events, Pneumonia to 3 (1.6%) 3 events.

  • On page 10, in 2nd paragraph of column 2 replace “final visit” with “last injection.”

  • On page 10, in 3rd paragraph of column 2 replace “discounted” with “discontinued.”

References

Boudreau, G, Finkelstein, I, Graboski, C, et al. OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. Can J Neurol Sci. 2022;49(4):540552. doi: 10.1017/cjn.2021.153 CrossRefGoogle ScholarPubMed